

## Further Update of Proposed USA Medicare Changes

### Highlights

- **One of the five (5) Medicare Administrative Contractors (MACs) proposing to limit local reimbursement coverage for MIGS procedures, National Government Services (NGS), has deferred the proposed implementation date of its Local Coverage Determination (LCD) from December 23, 2023, to March 23, 2024.**
- **NGS has announced the deferral to “allow more time to make decisions regarding comments received”.**
- **No announcements have so far been made by the other four (4) MACs that have also issued LCDs proposing to limit coverage of MIGS procedures.**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), today advises that the implementation date of the final draft of the local coverage determination (LCD) issued by National Government Services (**NGS**), has been deferred from December 23, 2023, to March 23, 2024.

National Government Services (NGS) administers the insurance reimbursement claims of healthcare facilities in the states of New York, Connecticut, Rhode Island, Massachusetts, Vermont, New Hampshire, Maine, Minnesota, Illinois, and Wisconsin.

NGS has posted on its website that it has deferred the implementation of the proposed LCD to “*allow further time to make decisions regarding comments received on LCD L37244 and on Article A56588 during the Notice Period*”.

The deferral by NGS is a positive outcome for the near-term sales of the Company’s *iTrack*<sup>™</sup> portfolio of canaloplasty devices, which have been performing strongly since the USA launch of the generation *iTrack*<sup>™</sup> *Advance* in the in May 2023. Reimbursement coverage of canaloplasty surgeries by NGS beyond March 23, 2024, will depend on whether the proposed LCD is implemented.

To date, five (5) MACs covering thirty-eight (38) states in the USA have issued local coverage determinations (LCDs) relating to MIGS procedures. There has so far been no announcement by the other four (4) MACs concerning deferrals, all of which have December 23, 2023, implementation dates.

***This release dated November 28, 2023, has been authorised for lodgement to ASX by the***

**Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.**

– ENDS –

**Company**

Tom Spurling  
Managing Director  
+61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

**Company**

Kate Hunt  
Chief Commercial Officer  
+61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

**Investors**

Mark Flynn  
Investor Relations  
+61 416 068 733  
[mflynn@nova-eye.com](mailto:mflynn@nova-eye.com)

---

**ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

---

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)

For personal use only